Feasibility and growth of a dedicated cardio-oncology service at a large victorian tertiary cardiac centre

Clicks: 1
ID: 323295
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #96 of 282 articles by views in European heart journal supplements : journal of the European Society of Cardiology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 282 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Advances in cancer therapy have significantly improved survival, however, cardiovascular toxicities during treatment and long-term cardiac complications remain an ongoing challenge. Dedicated cardio-oncology services aim to address this gap, yet real-world data on service growth and clinical impact are limited, particularly in Australia. A dedicated cardio-oncology service was established at a large Victorian tertiary cardiac centre, demonstrating feasibility and increasing service utilisation. Purpose This project audited the growth of a newly established cardio-oncology service to evaluate patterns of referral, cardiovascular management, and cancer treatment completion. We hypothesised that structured cardio-oncology care would support completion of cancer therapy with low rates of cardiovascular-related interruption. Methods A retrospective audit of all patients referred to the cardio-oncology service at a Victorian tertiary cardiac centre was undertaken between 1st July 2023 and 30th June 2025. Electronic medical records were reviewed to obtain baseline demographics, cancer diagnoses, cardiac investigations and medication changes. Primary outcomes included the percentage of cancer treatment completion, rates of hospitalisations and, mortality due to cardiovascular causes. Results 374 patients were included (mean age 65.4±14.9 years; 46% female, median follow up 13 months), total of 764 reviews. Cardiovascular comorbidities included hypertension (57%), dyslipidaemia (55%), diabetes (30%), smoking history (49%) and ischaemic heart disease (24%). Haematological malignancies were most common (32%), followed by breast (18%), lung (11%) and gastrointestinal cancers (11%). 50% of referrals occurred during active cancer treatment, heart failure being the main indication for referral (42%). Cardiovascular management changes occurred in the majority (69% with cardiovascular medication modifications, 502 echocardiograms, 50 cardiac MRI, 48 cardiac CT, 12 invasive angiograms performed). Only 9% (n=21/232) required a change/cessation in cancer treatment due to a cardiac cause. 1/36 patients died from a cardiovascular cause and 23 had cardiac hospitalisations (mostly for heart failure). Conclusion Dedicated cardio-oncology services are feasible and have demonstrated significant growth since inception in this tertiary Australian setting. Most patients were able to complete cancer treatment without interruption. These services may help reduce short- and long-term cardiovascular complications in oncology patients.New patients and total patient reviews Baseline demographics and outcomes
Reference Key
openalex_W7172261110 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors A Abeydeera, H S Yap, A Sahmeddini, S X Tan, A Murphy, S Ramkumar
Journal European heart journal supplements : journal of the European Society of Cardiology
Year 2026
DOI
10.1093/eurheartjsupp/suag097.202
URL
https://doi.org/10.1093/eurheartjsupp/suag097.202
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.